Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Monsoon
Raksha Bandhan
NV Ramana
Coronavirus India
Coronavirus Cases In India
75 years of Independence
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Covovax India launch by September; trial for kids soon: SII
India

Covovax India launch by September; trial for kids soon: SII

Covovax India launch by September; trial for kids soon: SII
Written by Siddhant Pandey
Jun 17, 2021, 12:48 am 2 min read
Covovax India launch by September; trial for kids soon: SII
The trials Novavax’s COVID-19 vaccine, called Covovax, are in the advanced stage.

The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September. The trials for the vaccine, called Covovax, are in the advanced stage of completion, SII CEO Adar Poonawalla said. Earlier this week, Novavax announced that the vaccine had been found over 90% effective against COVID-19. Here are more details.

Details
Vaccine trial likely to conclude by November

The trial for the vaccine in India is likely to conclude by November, Poonawalla was quoted as saying by CNBC-TV18. Novavax can apply for a vaccine license before its trial in India on the basis of data available from global trials, Poonawalla said. He said the firm is planning to start clinical trials of Covovax for children in July.

Trial
100% protection against moderate, severe infections: Novavax

Novavax said in a statement on Monday that its vaccine had demonstrated 100% protection against moderate and severe COVID-19 infection and a 90.4% efficacy overall. The study had enrolled 29,960 participants across 119 sites in the US and Mexico to assess the efficacy, safety, and immunogenicity of the vaccine. It demonstrated 93% efficacy against predominant Variants of Concern and Variants of Interest, Novavax said.

Recent news
Vaccine trial data promising, notes government

NITI Aayog member Dr. VK Paul told reporters on Tuesday that the SII has been conducting bridging trials for Novavax in India. The data shows that the vaccine is safe and effective, he said, adding that the trials are in the advanced stage of completion. The vaccine will be manufactured by the SII in large quantities, he said.

Quote
'Pace of vaccination should see renewed energy from next week'

Dr. Paul said, "The pace of vaccination should see a renewed energy from next week onwards when we will realign our efforts, state efforts, and effective scale-up at ground level is expected." "Teams both at the Centre and state are working on building new guidelines for high-speed coverage of the vaccination across the country," he added.

Commitments
Novavax has tiered pricing for lower/middle/upper-income countries

Novovax recently said that it has a "tiered" pricing scheme for lower-, upper-, and middle-income countries, comparable to most manufacturers. CEO Stanley C Erck said Monday, "Given that we've got a commitment of 1.1 billion doses with COVAX along with our partner Serum Institute (of India), a lot of our first doses are going to go into low- and middle-income countries, as they should."

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
Vaccine
Coronavirus
Serum Institute of India
Adar Poonawalla
Novavax
Related
Latest
Samsung Galaxy A33 5G receives latest Android security update
Samsung Galaxy A33 5G receives latest Android security update Technology
'John Wick: Chapter 4' director Chad Stahelski teases film details
'John Wick: Chapter 4' director Chad Stahelski teases film details Entertainment
Simona Halep wins the 2022 Canadian Open: Key stats
Simona Halep wins the 2022 Canadian Open: Key stats Sports
Bundesliga 2022-23, Bayern Munich beat Wolfsburg 2-0: Key stats
Bundesliga 2022-23, Bayern Munich beat Wolfsburg 2-0: Key stats Sports
2023 Kia Ray, with stylish looks, goes official: Check features
2023 Kia Ray, with stylish looks, goes official: Check features Auto
Vaccine
India to battle monkeypox with targeted 'ring vaccination' strategy
India to battle monkeypox with targeted 'ring vaccination' strategy India
Is SII developing vaccine for monkeypox? Here's what Poonawalla said
Is SII developing vaccine for monkeypox? Here's what Poonawalla said India
India's COVID-19 vaccination campaign crosses milestone of 2 billion doses
India's COVID-19 vaccination campaign crosses milestone of 2 billion doses India
COVID-19: India logs 20,044 fresh cases, 56 more fatalities
COVID-19: India logs 20,044 fresh cases, 56 more fatalities India
Free COVID-19 precaution dose for all adults from today
Free COVID-19 precaution dose for all adults from today India
More News
Coronavirus
Delhi makes mask mandatory, Rs. 500 fine imposed on violators
Delhi makes mask mandatory, Rs. 500 fine imposed on violators Delhi
All about the new Langya virus that has hit China
All about the new Langya virus that has hit China World
New COVID-19 sub-variant BA.2.75 detected in India: WHO
New COVID-19 sub-variant BA.2.75 detected in India: WHO India
How long does immunity last after COVID-19?
How long does immunity last after COVID-19? Technology
#NewsBytesExplainer: Why experts believe 4th COVID-19 wave is not coming
#NewsBytesExplainer: Why experts believe 4th COVID-19 wave is not coming India
More News
Serum Institute of India
India inching closer to launching its first dengue vaccine
India inching closer to launching its first dengue vaccine India
COVID-19 vaccine precautionary dose service charge capped at Rs. 150
COVID-19 vaccine precautionary dose service charge capped at Rs. 150 India
DCGI approves emergency use of Covovax in children above 12
DCGI approves emergency use of Covovax in children above 12 India
Govt panel okays phase-3 trials of Covovax as booster dose
Govt panel okays phase-3 trials of Covovax as booster dose India
SII to launch COVID-19 vaccine for children in 6 months
SII to launch COVID-19 vaccine for children in 6 months India
More News
Adar Poonawalla
EU body says it didn't receive application for Covishield approval
EU body says it didn't receive application for Covishield approval India
Serum to begin Covovax trials on children in July
Serum to begin Covovax trials on children in July India
Reports claiming fresh COVID-19 vaccine orders not placed baseless: Government
Reports claiming fresh COVID-19 vaccine orders not placed baseless: Government India
Getting aggressive calls from powerful people: SII CEO Adar Poonawalla
Getting aggressive calls from powerful people: SII CEO Adar Poonawalla India
Covishield price reduced to Rs. 300 for states: Adar Poonawalla
Covishield price reduced to Rs. 300 for states: Adar Poonawalla India
More News
Novavax
Serum gets nod for Novavax trial in 7-11 age group
Serum gets nod for Novavax trial in 7-11 age group India
Novavax seeks 'OK' for COVID-19 vaccine in needy countries first
Novavax seeks 'OK' for COVID-19 vaccine in needy countries first World
Expert panel says no to Covovax's children trials in India
Expert panel says no to Covovax's children trials in India India
How Biological E's coronavirus vaccine could be a potential gamechanger
How Biological E's coronavirus vaccine could be a potential gamechanger India
Novavax's COVID-19 vaccine is over 90% effective, firm says
Novavax's COVID-19 vaccine is over 90% effective, firm says India
More News
Related
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022